ATINYSE: ATI

BOLINGBROOK, Ill. , Nov. 4, 2024 /PRNewswire/ -- ATI Physical Therapy, Inc. (NYSE: ATIP) ("ATI" or the "Company"), a nationally recognized outpatient physical therapy provider in the United States, today reported financial results for the third quarter ended September 30, 2024.

Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for the November 6, 2024 shareholders meeting HALIFAX, Nova Scotia, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that the U.S. Food and Drug Administration (“FDA”) has provided positive feedback regarding the development strategy for ATI-1801, and agreed on the necessary registration package to support a New Drug Application (“NDA”). ATI-1801, a novel topical formulation of paromomycin (15% w/w), is under advanced clinical development for treating cutaneous leishmaniasis, a disfiguring skin infection affecting hundreds of thousands globally.

Allegheny Technologies (ATI) came out with quarterly earnings of $0.60 per share, missing the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.55 per share a year ago.

Ninth consecutive quarter with sales in excess of $1 billion Q3 2024 sales of $1.05 billion Q3 2024 net income attributable to ATI of $82.7 million, or $0.57 per share Aerospace & defense represent 62% of Q3 2024 sales Full year 2024 guidance updated Non-GAAP Information* Q3 adjusted net income attributable to ATI of $85.9 million, or $0.60 per share Q3 2024 ATI adjusted EBITDA of $185.7 million, or 17.7% of sales, up 100 basis points sequentially DALLAS , Oct. 29, 2024 /PRNewswire/ -- ATI Inc. (NYSE: ATI) reported third quarter 2024 results, with sales of $1.05 billion and net income attributable to ATI of $82.7 million, or $0.57 per share.     Sequential Y-O-Y ($ in millions except per share amounts) Q3 2024 Q2 2024 Change Q3 2023 Change Sales $1,051.2 $1,095.3 (4) % $1,025.6 2 % Net income attributable to ATI $82.7 $81.9 1 % $90.2 (8) % Earnings per share $0.57 $0.58 (2) % $0.62 (8) % Non-GAAP information* Adjusted net income attributable to ATI* $85.9 $86.0 — % $94.2 (9) % Adjusted earnings per share* $0.60 $0.60 — % $0.64 (6) % ATI adjusted EBITDA* $185.7 $182.6 2 % $162.6 14 % * Detailed reconciliations of the reported information under accounting principles generally accepted in the United States (U.S. GAAP) to adjusted non-GAAP figures are included in accompanying financial tables.

ATI Inc (NYSE:ATI ) Q3 2024 Results Conference Call October 29, 2024 8:30 AM ET Company Participants David Weston - Vice President of Investor Relations Kim Fields - President, CEO & Director Don Newman - Executive VP of Finance & CFO Conference Call Participants Richard Safran - Seaport Research Partners Andre Madrid - BTIG David Strauss - Barclays Phil Gibbs - KeyBanc Capital Markets Timna Tanners - Wolfe Research Seth Seifman - JPMorgan Scott Deuschle - Deutsche Bank Operator Hello, everyone, and welcome to ATI's Third Quarter 2024 Earnings Call. My name is Lydia, and I will be your operator today.

BOLINGBROOK, Ill. , Oct. 21, 2024 /PRNewswire/ -- ATI Physical Therapy, Inc. – ("ATI" or the "Company") (NYSE: ATIP), a nationally recognized outpatient physical therapy provider in the United States, today announced that it will release third quarter 2024 financial results on Monday, November 4, 2024, after the market closes.

ATI-1701 provides full protection against lethal tularemia in animal models after one year Company to provide update on tularemia vaccine candidate ATI-1701 and present new data on efficacy Presentation scheduled for 3:15 pm ET on October 17, 2024 HALIFAX, Nova Scotia, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that Gary Nabors, Ph.D., Chief Development Officer, and key members of Appili's scientific team, will participate at IDWeek 2024™, and present an update on the Appili biodefense program ATI-1701.

Allegheny Technologies (ATI) reachead $63.02 at the closing of the latest trading day, reflecting a +0.75% change compared to its last close.

The latest trading day saw Allegheny Technologies (ATI) settling at $62.83, representing a -1.83% change from its previous close.